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Abstract: The aim of this article is to propose meaningful guidance covering the practical and 
technical issues involved when planning or conducting clinical trials involving positron 
emission tomography (PET) guided radiotherapy. The complexity of imaging requirements will 
depend on the study aims, design and PET methods used. Where PET is used to adapt 
radiotherapy, a high level of accuracy and reproducibility is required to ensure effective and 
safe treatment delivery. The guidance in this document is intended to assist researchers 
designing clinical trials involving PET guided radiotherapy to provide sufficient information 
about the appropriate methods to complete PET-CT imaging to a consistent standard at 
participating centres. The guidance is divided into six categories: application of PET in 
radiotherapy, resource requirements, quality assurance (QA), imaging protocol design, data 
management and image processing. Each section provides an overview of the recent literature 
to support the specific recommendations. This guidance builds on previous recommendations 
from the National Cancer Research Institute (NCRI) PET Research Network and has been 
produced in collaboration with the National Radiotherapy Trials Quality Assurance Group 
(RTTQA). 
  
APPLICATION OF PET IN RADIOTHERAPY 
Positron emission tomography (PET) is an in vivo imaging technique used to explore biological 
processes at the cellular level to determine the extent of active disease and can often detect 
functional changes related to cancer treatment before anatomical imaging. PET-CT is a key 
investigative tool in cancer and is applied across a wide range of clinical indications determined 
by evidence based guidelines (1). PET-CT imaging has several important roles in radiotherapy 
clinical trials with differing levels of complexity (2): 
1. to assist in diagnosis and/or staging to determine eligibility for entry into a clinical trial 
that involves radiotherapy, 
2. for response assessment to monitor the effectiveness of a new or modified treatment, 
usually comprising a baseline scan and one or more follow up scans during or after a 
course of radiotherapy. Sometimes a PET imaging sub-study may be performed to 
determine the usefulness of PET for response assessment in a particular tumour type and 
treatment, involving radiotherapy, 
3. for treatment modification, with PET performed prior to or during radiotherapy to 
guide dose and/or treatment volumes, 
4. in pilot/phase I studies to evaluate the feasibility and safety of including PET in 
radiotherapy or the application of a new radiopharmaceutical to image relevant aspects 
of tumour biology, for example hypoxia, prior to a larger multicentre phase II/III study. 
The aim of this document is to present researchers with an overview of the technical and 
practical considerations in setting up radiotherapy clinical trials involving PET with the key 
recommendations summarised in Table 1. 
Summary of Recommendations 
1. Radiopharmaceutical selection may be dictated by availability and cost and researchers 
should explore this at an early stage in the study workup. 
2. PET-CT positioning needs to be optimised for radiotherapy planning in applications 
where accurate localisation of PET uptake on the planning images is essential. This will 
require use of an indexed flat couch overlay and immobilisation devices. 
3. A dedicated radiotherapy planning PET-CT should be acquired with the patient in the 
radiotherapy position for direct planning in advanced delivery techniques, image 
guided and adaptive radiotherapy and applications where the PET signal is used to 
define sub-volumes or voxels within the tumour for dose escalation or ‘dose painting’. 
4. PET-CT scanners should be accredited to ensure quantitative results are consistent 
across centres. 
5. For applications requiring the most accurate and reproducible positioning, the PET-CT 
should be commissioned for radiotherapy planning purposes and be included within 
the radiotherapy quality assurance (QA) system. 
6. A nuclear medicine physician/radiologist and medical physics expert (MPE) with 
experience in PET should be involved in the protocol development. 
7. A standardised imaging protocol should be provided to centres identifying critical 
requirements to achieve the trial outcomes.  
8. The CT parameters for the PET-CT will need to be optimised for delineation if 
replacing the radiotherapy planning CT for direct planning. 
9. Experienced radiotherapy radiographers should position patients on the PET-CT 
scanner for applications requiring high accuracy and reproducibility. 
10. Integrity of PET data should be tested throughout the anonymisation and data transfer 
process to ensure quantitative values and volumes are preserved. 
11. Registration techniques (rigid or non-rigid) should be validated for the intended 
application to assess the registration accuracy and registered images verified on a per 
patient basis. 
12. Volume delineation guidelines should be developed for the intended application to 
improve reproducibility across centres. For complex planning applications, a series of 
benchmark cases should be provided to individual centres for training. 
13. Automated segmentation techniques should be validated for the intended application. 
14. Volumes derived using automated segmentation algorithms must be visually 
inspected by the clinical oncologist on a per patient basis and manually edited where 
appropriate. 
Table 1. Summary of Recommendations 
RESOURCE REQUIREMENTS 
Radiopharmaceuticals for Oncology Applications 
The most commonly used radiopharmaceutical for PET imaging, and hence radiotherapy 
clinical trials, is 18F-Fluorodeoxyglucose (FDG).  FDG is an analogue of glucose, which has 
higher uptake in areas with increased glucose transport and metabolism including many 
cancers. 18F-FDG PET has high sensitivity in many cancer types (3), however it is not ‘specific’ 
for malignant disease, being taken up in other processes with increased glucose turnover such 
as infection and inflammation. 
Other radiopharmaceuticals have been developed to investigate specific biochemical processes 
for imaging in cancer, including hypoxia, protein and cell membrane synthesis, amino acid 
transport, somatostatin receptor and protein binding (4,5). Table 2 provides a summary of the 
primary targets in current PET imaging of cancer that have potential applications in 
radiotherapy. 
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Table 2. A summary of some of the primary targets in current PET imaging of cancer with potential for 
radiotherapy applications. 
11C, 18F and 60/61/64Cu are produced in a cyclotron, while 68Ga and 62Cu are generator produced. 
The short half-life of 11C (20 minutes) means that studies utilising 11C radiopharmaceuticals need 
to be carried out at centres with an onsite cyclotron. Radiopharmaceutical selection may be 
dictated by availability and cost, particularly for non-FDG radiotracers and researchers should 
explore this at an early stage in the study workup. 
Equipment for PET Guided Radiotherapy  
All major radiotherapy centres in the UK have access to clinical PET-CT imaging services, 
however they may not be in the same location nor have the same provider as the radiotherapy 
service. Most clinical PET-CT scanners have the capability to perform imaging to aid 
radiotherapy planning, however access to specialist radiotherapy equipment (external lasers, 
flat bed and immobilisation devices etc) will vary between centres limiting the range of 
radiotherapy work that can be performed. 
PET imaging for diagnosis and response assessment would generally incorporate standard 
clinical PET-CT imaging procedures into the trial protocol. However, patient positioning for 
clinical PET-CT is optimised for image quality whilst trying to maintain patient comfort and 
often this does not reflect positioning used for radiotherapy planning. Different arm 
positioning, the use of a curved couch and shallow or free breathing can result in significantly 
different patient positioning in the diagnostic PET-CT compared to radiotherapy planning 
images. 
For some simple planning applications, such as deciding whether to include or exclude 
structures and for assisting in determining the disease extent alongside other imaging, standard 
PET-CT positioning and visual comparison of anatomy without registration may be acceptable 
if the clinician is able to adequately localise the PET uptake. However, where accurate 
localisation of PET uptake on the planning images is essential, the PET-CT needs to be 
optimised for radiotherapy planning. 
• For studies requiring high registration accuracy and reproducibility, the PET-CT should 
be performed in the radiotherapy position (or as close as possible) using an indexed flat 
couch overlay and immobilisation devices as appropriate. The CT component of the 
PET-CT is then used to register the PET to the radiotherapy planning (RTP) CT to aid in 
delineation of the gross tumour volume (GTV). This is sometimes termed as ‘in-direct’ 
planning (6).  
• When the PET-CT is acquired with the patient in their radiotherapy position using a flat, 
indexed couch overlay and immobilisation, the CT component of the PET-CT can be 
adapted to replace the RTP CT and used ‘directly’ for delineation of target volumes and 
healthy tissues. This is often referred to as ‘direct’ planning. 
Acquiring a dedicated planning PET-CT for direct planning removes the errors associated with 
acquisition and registration of images at different timepoints, which is the preferred option for 
applications requiring the highest levels of accuracy.  This includes advanced delivery 
techniques, image guided and adaptive radiotherapy and applications where the PET signal is 
used to define sub-volumes or voxels within the tumour for dose escalation or ‘dose painting’ 
(6). It is however the most complex option and requires access to specialist equipment and 
expertise that will not be available at all PET-CT centres. Whilst in-direct planning is more 
accurate than using standard clinical PET-CT positioning, errors can still be introduced during 
patient set up and/or registration and centres will still need access to specialist equipment and 
expertise. 
Staffing Requirements 
A nuclear medicine physician/radiologist with experience in PET-CT should be part of the 
protocol development group and involved in ongoing trial management to provide advice and 
support for the imaging aspects of the study design and in applying for research approvals. 
Detailed information about licences and research authorisations required for the administration 
of radioactive substances can be found in the Administration of Radioactive Substances 
Advisory Committee (ARSAC) Notes for Guidance (7) and on the NHS Health Research 
Authority website (8).  
Medical physics experts (MPE) from the lead centre should be consulted at an early stage of 
trial design to provide advice on the scientific and technical aspects of the protocol, including 
quality control (QC) requirements, radiation dose assessments and safety considerations. It is 
unlikely a single MPE will have appropriate experience in both radiotherapy and PET therefore 
advice will be required from both PET and radiotherapy physics experts. 
Individual roles and responsibilities for the provision of radiotherapy and PET imaging 
procedures at recruiting centres will vary depending on local arrangements and levels of 
expertise. For successful implementation of the protocol at the recruiting centres, there will 
need to be close collaboration between radiotherapy and nuclear medicine/PET staff. Existing 
levels of staff training will vary between centres and the lead investigator centre may need to 
provide support and advice for more complex study designs to ensure the required level of 
expertise in both PET and radiotherapy are achieved.  
QUALITY ASSURANCE 
Routine PET-CT Quality Control 
The choice of acquisition and reconstruction parameters directly impacts on bias and variation 
in quantitative PET metrics which will in turn affect delineation for radiotherapy applications. 
To minimise bias and variation and achieve comparable quantitative results across scanning 
centres, it is important to implement standardised imaging protocols and regular QC 
procedures. Recommended minimum requirements for routine PET-CT QC are described in the 
Institute of Physics and Engineering in Medicine (IPEM) Report 108 (9) and CT specific QC is 
covered in IPEM report 91 (10). Use of standard phantoms is an accepted method for matching 
PET image quality and quantitative performance between centres and can be achieved by 
ensuring participating PET-CT scanners have been accredited through national or international 
accreditation programmes such as that provided by the UK PET Core Lab (11) or European 
Association of Nuclear Medicine (EANM) (12). 
Radiotherapy Specific Quality Control 
For applications requiring the most accurate and reproducible positioning, the PET-CT will 
require immobilisation consistent with the radiotherapy set up, external radiotherapy lasers and 
an indexed couch overlay. The PET-CT will also need commissioning for radiotherapy planning 
purposes and be included within the radiotherapy quality assurance (QA) system. Test 
procedures and tolerances should follow national and international guidance (13,14) with input 
from an experienced radiotherapy physicist (MPE) to ensure appropriate tests are defined and 
tolerances set for in-direct and direct planning applications.  
Commissioning and routine QC tests of the PET-CT should cover the couch, external lasers and 
set up accuracy and should mirror that required for the radiotherapy CT simulator. For direct 
treatment planning, where the CT component of the PET-CT acquisition replaces the RTP CT, 
additional tests are required to ensure accuracy of dose calculation and delineation. Regular 
tests using point or line sources should be included as part of the routine QC schedule to assess 
the accuracy of the PET to CT alignment. This should be repeated after the gantries are 
separated for servicing and be performed with and without weight on the couch (15). 
IMAGING PROTOCOL DESIGN 
PET Protocol 
There are several technical, physical and biological factors known to affect quantification in PET 
imaging (16). To minimise variation in PET results between centres, it is recommended to 
provide centres with an imaging protocol based on the latest EANM guidelines (17). Whilst 
these guidelines focus on 18F-FDG PET, the general principles apply for non-FDG tracers. 
Additional advice should be sought from a nuclear medicine physician/radiologist with 
experience in PET-CT to determine trial specific requirements. Ideally the imaging protocol 
should identify the critical time points in the radiotherapy pathway and essential imaging 
requirements along with how much centres can deviate without compromising the trial 
outcomes. For studies using PET to monitor changes in uptake over time, subsequent PET-CT 
scans should be performed on the same scanner whenever possible with patient preparation, 
positioning and acquisition matched as closely as possible to the baseline scan to minimise 
variability. Consideration should also be given to any information to be collected at the time of 
imaging, such as patient preparation (e.g. fasting, blood glucose level), and a form provided 
with the imaging protocol for the local imaging staff to complete.  
Local practice for injected activities varies across centres. The ARSAC Notes for Guidance (7) 
provide diagnostic reference levels (DRLs) for the majority of PET radiotracers and this should 
be used to determine dose constraints for clinical trials in accordance with the Ionising 
Radiation (Medical Exposure) Regulations (18,19). Some centres may have optimised local 
protocols using lower administered activities such as the weight-based regimes for adults and 
paediatrics suggested by the EANM (17,20). To allow for variation across centres, the ARSAC 
DRL should be used in the research application and imaging protocol, but with allowance for 
centres to use lower injected activities where appropriate.  
CT Protocol 
In clinical practice the CT acquired as part of a PET-CT scan is used for attenuation correction of 
PET data and to provide anatomical information for localisation of the tracer uptake. The 
current national DRL for the CT acquired as part of a half-body PET-CT (base of brain to mid-
thigh) is 60% lower than that for a diagnostic chest, abdomen and pelvis CT scan (21,22). As a 
result, the image quality is not appropriate for direct delineation of radiotherapy volumes. For 
direct planning applications the CT acquired as part of the PET-CT needs to be adapted to 
produce equivalent image quality to the radiotherapy planning CT it will replace. 
Motion Management Techniques 
A range of immobilisation devices and positioning tools are available for optimal positioning of 
patients for radiotherapy planning, depending on the treatment site. This may include vacuum-
bags, knee rests, foam mattresses, foot or head rests as well as indexed boards for different 
anatomical regions. PET centres will not have direct access to these devices and so a system 
must be established for transfer of devices to the imaging site on a per patient basis. 
Alternatively, funding may be required to purchase duplicates for the imaging site.   
For direct and some in-direct applications of PET-CT for treatment planning where accuracy 
and reproducibility of patient positioning is critical, experienced radiotherapy radiographers 
should position the patients on the PET-CT scanner as they would on a CT simulator. 
For direct or in-direct planning procedures involving thoracic lesions, it may be desirable to 
compensate for respiratory motion using software or hardware gating techniques (4D-PET-CT) 
to improve quantification accuracy and aid in tumour volume delineation (23,24). Respiratory 
gating is not standard for PET-CT, so it should be determined whether respiratory gating 
equipment is available at the designated PET centres. Any respiratory gating method used for 
radiotherapy planning must be compatible with the treatment planning system (TPS) and the 
process validated with phantoms and/or patients prior to implementation in a radiotherapy 
planning application. 
DATA MANAGEMENT 
To reduce processing time and storage space on the PET-CT scanner, most PET studies are 
acquired in 'frame mode'. This mode stores PET data in sinograms and uses pre-defined 
computer storage and memory resources. This is known as ‘raw’ data. Few centres routinely 
store raw PET data for clinical PET-CT studies, but this can be useful in the research setting if 
the incorrect reconstruction was used or if retrospective reconstructions are required. Most 
centres can store raw PET data as Digital Imaging and Communications in Medicine (DICOM) 
encapsulated files on a standard picture archiving and communication system (PACS). 
However, as the raw data is in proprietary vendor-specific format it can only be reconstructed 
on the PET-CT scanner or using specialised research tools.  
Once the PET and CT data have been acquired, the raw data is reconstructed into stacks of axial 
slices which are then used for clinical review or data analysis. Reconstructed images are 
routinely sent to a local PACS for long term storage. As standard, centres should reconstruct the 
CT used for attenuation correction (CTAC), the CT used for clinical review (which may have 
different parameters to the CTAC reconstruction), the non-attenuation corrected PET (to aid in 
reviewing attenuation artefacts) and the attenuation corrected PET. For direct PET-CT there will 
also be reconstructions designed specifically for the RTP CT. 
Reconstructed PET-CT imaging data should be stored in a DICOM compliant format (25) to 
allow transfer of images across different storage media and reviewing/planning software. The 
choice of system for clinical review and volume delineation (nuclear medicine reporting 
workstation or TPS) may depend on the ability of the software to display fused PET-CT data in 
units of SUV and availability of the desired manual or automated tools for delineation. If 
volume delineation is performed on the PET/nuclear medicine software, volumes must be 
stored as DICOM compliant radiotherapy structure sets to ensure they can be read into the TPS. 
A tested and secure method (26,27) for transferring scans from the PET-CT scanner to the final 
location for reporting and/or delineation must be in place. 
Information about the patient and the image acquisition and reconstruction is stored within the 
DICOM header of the images. For research studies, the PET-CT data needs to be anonymised to 
remove patient identifiable information from these header fields for centralised storage. During 
anonymisation and post-processing of images, some software may delete or modify DICOM 
fields required for quantification. As part of ongoing quality control of image data it is 
important that these DICOM fields are checked to ensure that data integrity is maintained after 
anonymisation and transfer (28).  
IMAGE PROCESSING 
Image Registration 
For in-direct planning applications,  the PET-CT images are registered to the RTP CT to aid in 
the delineation of target volumes and normal tissues (6). This involves applying a registration 
algorithm to register the CT component of the PET-CT to the RTP CT then applying the 
transformation matrix to the PET data. As the spatial resolution of the PET is much lower than 
the RTP CT, registration will result in resampling of the PET voxels to match the CT thus 
affecting voxel values.  
Local and global registration accuracy will depend on the anatomical site, extent of 
deformation, image quality and registration algorithm used. The impact of registration errors 
on the treatment delivery depends on the accuracy required for the intended application and 
whether the errors will be propagated throughout the treatment plan (29). An application- and 
anatomical site-specific evaluation of the registration accuracy should be performed as 
described in the American Association of Physicists in Medicine (AAPM) Report 132 and 
registered images should be verified on a per-patient basis (29). 
There are three categories of registration techniques: 
• rigid registration is a linear transformation that includes translation and rotation only 
preserving the distances between all points in the image 
• affine registration is also linear, but in addition to translation and rotation, includes 
scaling, shearing and plane reflection. Distances between points in the image are not 
preserved but parallel lines remain parallel 
• deformable registration is a non-linear transformation and maps points from one image 
to another 
If the patient positioning for the PET-CT closely matches the RTP CT and there has not been 
significant anatomical changes, rigid registration or rigid registration over a limited field of 
view may be sufficient to assist in visualising tissues for volume delineation (29,30). Deformable 
registration techniques may be suitable where patient positioning is not well matched, or the 
anatomy has changed, however has some limitations (29). In particular, application of the 
transformation matrix from the CT to the PET can provide accurate registration of tissue 
boundaries, however due to lack of structural information, accurate registration of the interior 
tissue structure can be variable and may result in large voxel-to-voxel differences (31). 
Deformable registration techniques are therefore unsuitable for applications utilising PET voxel 
values or gradients for response assessment to adapt the radiotherapy plan. In these cases, the 
recommended procedure is to acquire a dedicated PET-CT in the radiotherapy position for 
direct planning. Many centres do not have access to multimodality deformable registration 
algorithms and the implementation will be software dependent requiring each to be validated 
for the intended trial application.  
Volume Delineation  
In radiotherapy planning applications the PET may be used alongside other imaging to help 
guide the oncologist in delineating the primary GTV on the RTP CT. Where PET is known to be 
more sensitive than CT, it may also be used in the decision to include or exclude lymph nodes 
within the planning target volume (PTV) based on tracer uptake (6). In this case, volumes will 
usually be delineated on the RTP CT following established practice and a margin added to 
account for microscopic disease. Manual or automatic segmentation techniques can also be used 
for delineation of tracer-avid sub-volumes for dose painting or biologically conformal 
radiotherapy applications (30).  
The use of PET to aid in manual volume delineation can improve reproducibility compared to 
CT alone, however can be subject to inter-observer variability (32,33).  To improve consistency 
of volume delineation across centres, outlining guidelines should be included in the trial 
protocol (34). The guidelines should include standardised colour scale and windowing settings 
for visualisation of PET uptake as these can influence the lesion margins (35). Volume 
delineation should be performed by a clinical oncologist and nuclear medicine 
physician/radiologist together to ensure accurate interpretation of the PET uptake. For more 
complex planning applications, the use of benchmark cases is recommended. These can be 
accessed by centres prior to the trial opening to monitor delineation consistency and provide a 
consensus on the use of PET across recruiting centres. 
Automated segmentation algorithms can be classified into two broad groups: simple threshold-
based techniques (fixed or adaptive) and more advanced algorithms (36). Threshold-based 
techniques are computationally simple to implement, however do not perform well with 
smaller lesions or complex structures (non-spherical or non-uniform uptake) making them 
unsuitable for accurate volume delineation in many radiotherapy applications (37). The chosen 
threshold is also dependent on the characteristics of the scanner and the reconstructed images 
so requires prior knowledge of each scanner along with strict adherence to imaging protocols at 
all participating centres. 
To overcome the limitations of manual and threshold segmentation techniques, several 
advanced automated segmentation algorithms have been developed for delineation of PET 
volumes. The AAPM have published a review of these proposed algorithms including the 
advantages and limitations of each type (36). It is important to note however, that few are 
widely available and most are not fully validated, therefore no single method is recommended 
(30). Where automated segmentation methods are to be used in a trial, they should be validated 
for the intended application and critically verified by a physician. No current automated 
segmentation algorithm is accurate across all patients and anatomical sites, therefore volumes 
derived using automated segmentation algorithms must be visually inspected by the clinical 
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